• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

G蛋白-SNARE相互作用的无标记检测及小分子调节剂的筛选

Label-free detection of G protein-SNARE interactions and screening for small molecule modulators.

作者信息

Wells Christopher A, Betke Katherine M, Lindsley Craig W, Hamm Heidi E

机构信息

Department of Pharmacology Vanderbilt University Medical Center 442 Robinson Research Building 23rd Ave. South @ Pierce Nashville, Tennessee 37232-6600.

出版信息

ACS Chem Neurosci. 2012 Jan 18;3(1):69-78. doi: 10.1021/cn200102d.

DOI:10.1021/cn200102d
PMID:22368765
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3285104/
Abstract

G(i/o)-coupled presynaptic GPCRs are major targets in neuropsychiatric diseases. For example, presynaptic auto- or heteroreceptors include the D(2) dopamine receptor, H(3) histamine receptor, 5HT(1) serotonin receptors, M(4) acetylcholine receptors, GABA(B) receptors, Class II and III metabotropic glutamate receptors, opioid receptors, as well as many other receptors. These GPCRs exert their influence by decreasing exocytosis of synaptic vesicles. One mechanism by which they act is through direct interaction of the Gβγ subunit with members of the SNARE complex downstream of voltage-dependent calcium channels, and specifically with the C-terminus of SNAP25 and the H3 domain of syntaxin1A(1-3). Small molecule inhibitors of the Gβγ-SNARE interaction would allow the study of the relative importance of this mechanism in more detail. We have utilized novel, label-free technology to detect this protein-protein interaction and screen for several small molecule compounds that perturb the interaction, demonstrating the viability of this approach. Interestingly, the screen also produced enhancers of the Gβγ-SNARE interaction.

摘要

G(i/o)偶联的突触前G蛋白偶联受体(GPCRs)是神经精神疾病的主要靶点。例如,突触前自身或异源受体包括D(2)多巴胺受体、H(3)组胺受体、5HT(1)5-羟色胺受体、M(4)乙酰胆碱受体、GABA(B)受体、II类和III类代谢型谷氨酸受体、阿片受体以及许多其他受体。这些GPCRs通过减少突触小泡的胞吐作用发挥其影响。它们起作用的一种机制是通过Gβγ亚基与电压依赖性钙通道下游的SNARE复合体成员直接相互作用,特别是与SNAP25的C末端和Syntaxin1A的H3结构域相互作用(1-3)。Gβγ-SNARE相互作用的小分子抑制剂将有助于更详细地研究这种机制的相对重要性。我们利用了新型的无标记技术来检测这种蛋白质-蛋白质相互作用,并筛选了几种干扰这种相互作用的小分子化合物,证明了这种方法的可行性。有趣的是,筛选还产生了Gβγ-SNARE相互作用的增强剂。

相似文献

1
Label-free detection of G protein-SNARE interactions and screening for small molecule modulators.G蛋白-SNARE相互作用的无标记检测及小分子调节剂的筛选
ACS Chem Neurosci. 2012 Jan 18;3(1):69-78. doi: 10.1021/cn200102d.
2
Gbetagamma interferes with Ca2+-dependent binding of synaptotagmin to the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex.Gβγ干扰突触结合蛋白与可溶性N-乙基马来酰亚胺敏感因子附着蛋白受体(SNARE)复合体的钙离子依赖性结合。
Mol Pharmacol. 2007 Nov;72(5):1210-9. doi: 10.1124/mol.107.039446. Epub 2007 Aug 22.
3
Disabling the Gβγ-SNARE interaction disrupts GPCR-mediated presynaptic inhibition, leading to physiological and behavioral phenotypes.阻断 Gβγ-SNARE 相互作用会破坏 GPCR 介导的突触前抑制,导致生理和行为表型。
Sci Signal. 2019 Feb 19;12(569):eaat8595. doi: 10.1126/scisignal.aat8595.
4
A Presynaptic Group III mGluR Recruits Gβγ/SNARE Interactions to Inhibit Synaptic Transmission by Cone Photoreceptors in the Vertebrate Retina.突触前III组代谢型谷氨酸受体通过募集Gβγ/SNARE相互作用来抑制脊椎动物视网膜中视锥光感受器的突触传递。
J Neurosci. 2017 Apr 26;37(17):4618-4634. doi: 10.1523/JNEUROSCI.2948-16.2017. Epub 2017 Mar 31.
5
SNAP25 differentially contributes to G-coupled receptor function at glutamatergic synapses in the nucleus accumbens.可溶性 NSF 附着蛋白 25(SNAP25)对伏隔核谷氨酸能突触处 G 蛋白偶联受体功能的贡献存在差异。
Front Cell Neurosci. 2023 May 2;17:1165261. doi: 10.3389/fncel.2023.1165261. eCollection 2023.
6
Gβγ SNARE Interactions and Their Behavioral Effects.Gβγ SNARE 相互作用及其行为效应。
Neurochem Res. 2019 Mar;44(3):636-649. doi: 10.1007/s11064-018-2531-x. Epub 2018 May 11.
7
Gβγ Binds to the Extreme C Terminus of SNAP25 to Mediate the Action of Gi/o-Coupled G Protein-Coupled Receptors.Gβγ与SNAP25的极端C末端结合,以介导Gi/o偶联的G蛋白偶联受体的作用。
Mol Pharmacol. 2016 Jan;89(1):75-83. doi: 10.1124/mol.115.101600. Epub 2015 Oct 30.
8
Synaptic Integration of Subquantal Neurotransmission by Colocalized G Protein-Coupled Receptors in Presynaptic Terminals.突触前末梢中共定位的 G 蛋白偶联受体对亚量子神经传递的突触整合作用。
J Neurosci. 2022 Feb 9;42(6):980-1000. doi: 10.1523/JNEUROSCI.0035-21.2021. Epub 2021 Dec 23.
9
Modulation of neurotransmission by GPCRs is dependent upon the microarchitecture of the primed vesicle complex.G 蛋白偶联受体对神经递质的调制依赖于已被激活的囊泡复合物的微结构。
J Neurosci. 2014 Jan 1;34(1):260-74. doi: 10.1523/JNEUROSCI.3633-12.2014.
10
Gβγ and the C terminus of SNAP-25 are necessary for long-term depression of transmitter release.Gβγ 和突触融合蛋白 25 的 C 末端对于递质释放的长时程抑制是必需的。
PLoS One. 2011;6(5):e20500. doi: 10.1371/journal.pone.0020500. Epub 2011 May 25.

引用本文的文献

1
Reversal of Ethanol-induced Intoxication by a Novel Modulator of Gβγ Protein Potentiation of the Glycine Receptor.一种新型甘氨酸受体Gβγ蛋白增强调节剂对乙醇诱导的中毒的逆转作用。
J Biol Chem. 2016 Sep 2;291(36):18791-8. doi: 10.1074/jbc.M116.740555. Epub 2016 Jul 11.
2
Regulation of neuronal GABA(B) receptor functions by subunit composition.神经元 GABA(B) 受体功能的亚基组成调节。
Nat Rev Neurosci. 2012 May 18;13(6):380-94. doi: 10.1038/nrn3249.
3
GPCR mediated regulation of synaptic transmission.G 蛋白偶联受体介导的突触传递调节。
Prog Neurobiol. 2012 Mar;96(3):304-21. doi: 10.1016/j.pneurobio.2012.01.009. Epub 2012 Jan 28.

本文引用的文献

1
Gβγ and the C terminus of SNAP-25 are necessary for long-term depression of transmitter release.Gβγ 和突触融合蛋白 25 的 C 末端对于递质释放的长时程抑制是必需的。
PLoS One. 2011;6(5):e20500. doi: 10.1371/journal.pone.0020500. Epub 2011 May 25.
2
Inhibition of Ca2+ channels and adrenal catecholamine release by G protein coupled receptors.G 蛋白偶联受体对钙通道和肾上腺儿茶酚胺释放的抑制作用。
Cell Mol Neurobiol. 2010 Nov;30(8):1201-8. doi: 10.1007/s10571-010-9596-7.
3
Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.卤代 N-(2-(4-氧代-1-苯基-1,3,8-三氮杂螺[4.5]癸烷-8-基)乙基)苯甲酰胺的设计、合成与生物评价:一种同工酶选择性小分子磷脂酶 D2 抑制剂的发现。
J Med Chem. 2010 Sep 23;53(18):6706-19. doi: 10.1021/jm100814g.
4
Noradrenaline inhibits exocytosis via the G protein βγ subunit and refilling of the readily releasable granule pool via the α(i1/2) subunit.去甲肾上腺素通过 G 蛋白βγ亚基抑制胞吐作用,通过α(i1/2)亚基再填充易释放颗粒池。
J Physiol. 2010 Sep 15;588(Pt 18):3485-98. doi: 10.1113/jphysiol.2010.190090. Epub 2010 Jul 19.
5
Presynaptic G-protein-coupled receptors dynamically modify vesicle fusion, synaptic cleft glutamate concentrations, and motor behavior.突触前G蛋白偶联受体动态调节囊泡融合、突触间隙谷氨酸浓度和运动行为。
J Neurosci. 2009 Aug 19;29(33):10221-33. doi: 10.1523/JNEUROSCI.1404-09.2009.
6
Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity.同工型选择性磷脂酶D(PLD)抑制剂的设计与合成。第二部分。产生PLD2选择性的1,3,8-三氮杂螺[4,5]癸-4-酮优势结构的鉴定。
Bioorg Med Chem Lett. 2009 Apr 15;19(8):2240-3. doi: 10.1016/j.bmcl.2009.02.125. Epub 2009 Mar 6.
7
Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.亚型选择性磷脂酶D(PLD)抑制剂的设计与合成。第一部分:用于PLD1特异性的替代卤代优势结构的影响。
Bioorg Med Chem Lett. 2009 Apr 1;19(7):1916-20. doi: 10.1016/j.bmcl.2009.02.057. Epub 2009 Feb 20.
8
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.调节癌细胞侵袭性的亚型选择性磷脂酶D抑制剂的设计。
Nat Chem Biol. 2009 Feb;5(2):108-17. doi: 10.1038/nchembio.140. Epub 2009 Jan 11.
9
G protein betagamma subunits modulate the number and nature of exocytotic fusion events in adrenal chromaffin cells independent of calcium entry.G蛋白βγ亚基可独立于钙内流调节肾上腺嗜铬细胞中胞吐融合事件的数量和性质。
J Neurophysiol. 2008 Nov;100(5):2929-39. doi: 10.1152/jn.90839.2008. Epub 2008 Sep 24.
10
Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles.作为中枢神经系统治疗药物的小分子蛋白质-蛋白质相互作用抑制剂:当前进展与未来障碍
Neuropsychopharmacology. 2009 Jan;34(1):126-41. doi: 10.1038/npp.2008.151. Epub 2008 Sep 17.